Black and Hispanic patients, along with those lacking commercial insurance, face nearly a 50% higher risk of experiencing delays in starting neoadjuvant chemotherapy (NACT) for muscle-invasive bladder cancer (MIBC), according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Led by Dr. Margaux Wooster of the Herbert Irving Comprehensive Cancer Center, the study analyzed 5,260 patient records to identify systemic barriers to timely cancer care.
Why do treatment delays occur in muscle-invasive bladder cancer?
Delays in starting NACT beyond 60 days of diagnosis are linked to poorer clinical outcomes, prompting investigators to examine system-level factors. Dr. Wooster’s retrospective cohort study, utilizing the National Cancer Database, found that 48.4% of the 5,260 patients studied experienced treatment delays. While tumor-specific factors like T-stage and N-stage did not significantly correlate with wait times, socioeconomic status and insurance type emerged as primary drivers of inequity.
The study revealed that for patients over 70, every additional year of age was associated with a 0.82-day decrease in time to treatment initiation, suggesting that clinical urgency may be prioritized differently for older patient populations.
How do insurance and demographics influence care timelines?
Insurance status serves as a major determinant in how quickly a patient receives chemotherapy, according to the data. Patients covered by Medicaid were 1.62 times more likely to face delays compared to those with other insurance types. Similarly, residency in lower-income zip codes increased the odds of delay by 1.61. These findings suggest that the administrative burden of insurance authorization or the proximity to specialized care centers creates significant hurdles for vulnerable populations.
Geographic and institutional disparities
The study identified unexpected trends regarding where patients seek care. Individuals treated at academic centers were 1.50 times more likely to experience delays than those treated elsewhere, and patients in the Northeast region faced a 1.73 increased risk. Researchers suggest these findings indicate that high-volume academic centers may struggle with patient throughput or complex scheduling, even while providing specialized cancer services.
What steps can health systems take to promote equity?
Future interventions must target the transition period between initial diagnosis and the start of systemic therapy. Dr. Wooster and her team emphasize that identifying these high-risk groups allows for targeted navigation programs. By streamlining referral processes for underinsured patients and improving scheduling efficiency at academic institutions, health systems could mitigate the 60-day delay threshold that currently compromises patient outcomes.
Patients and caregivers should ask their oncology team specifically about the “time to treatment initiation” (TTI) targets upon receiving an MIBC diagnosis to ensure their care plan remains on schedule.
Frequently Asked Questions
- What is the standard timeframe for NACT initiation?
Clinical guidelines suggest that delays exceeding 60 days between diagnosis and the start of neoadjuvant chemotherapy can negatively impact cancer-related outcomes. - Are tumor characteristics the main cause of treatment delays?
No. According to the study, tumor T and N stages were not significantly associated with delays; socioeconomic factors and insurance status were the primary drivers. - Does age impact how quickly treatment begins?
Yes. In patients over 70, the study found that increasing age was associated with shorter wait times, indicating that clinicians may prioritize older patients for faster intervention.
Are you or a loved one navigating a cancer diagnosis? Subscribe to our patient advocacy newsletter for the latest updates on equitable care standards and actionable resources for managing clinical timelines.
